UPDATE 2-Higher rate of heart problems seen with Amgen bone drug in trial

May 21 (Reuters) – Amgen Inc and UCB SA

said on Sunday they did not expect their experimental

osteoporosis drug to win U.S. approval this year after a higher

rate of serious heart-related side effects were observed in a

late-stage clinical trial.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s